Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a405becd4947ee28

Jump to content

Talk:EyePoint, Inc.

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 4 months ago by Spintendo in topic Proposed Changes to EyePoint

Proposed Changes to EyePoint

[edit]

Hello,

I am an agency partner of EyePoint and am disclosing a conflict of interest in accordance with Wikipedia’s COI guidelines.

I’d like to propose factual updates to the Leadership, Company Activities, and Clinical research sections to reflect recent developments at the company. The intent is to improve accuracy and keep the article current, using independent, reliable sources.

Proposed change (suggested wording):

  1. Proposed additional section "Leadership and Company Activities" and proposed language -
    1. In January 2026, EyePoint Pharmaceuticals changed its name to EyePoint, Inc., according to reporting by Tipranks.
    2. As of 2026, EyePoint, Inc. is engaged in developing sustained-release therapeutics and treatments for patients with serious retinal diseases, which has been covered by independent reliable sources such as Bloomberg  and Yahoo Finance. These sources describe the development focus as “developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.”
    3. In July 2023, Jay S. Duker, M.D. was appointed as President & CEO of EyePoint. Duker joined EyePoint in 2016 as an independent member of the company’s board of directors and transitioned to part-time chief strategic scientific officer in 2020, followed by full-time chief operating officer in 2021, before becoming President and CEO, according to coverage by Healio OSN.  
  2. Proposed additional section "Clinical research" and proposed language -
    1. EYP-1901 (DURAVYU) is being developed by EyePoint for the treatment of VEGF-mediated retinal diseases.
    2. According to independent reporting by Ophthalmology Advisor, Clinical Trials Arena, and Ophthalmology Times, the company is conducting pivotal Phase 3 clinical trials of EYP-1901 for the treatment of wet age-related macular degeneration (wet AMD). The trials are registered on ClinicalTrials.gov under identifier NCT06668064 for LUGANO and NCT06683742 for LUCIA.
    3. According to coverage by Ophthalmology Times, the company is also conducting pivotal Phase 3 clinical trials of EYP-1901 for the treatment of diabetic macular edema (DME).

Please let me know if this wording is acceptable or if adjustments are needed. Thank you for your time and review. ~2026-78941-5 (talk) 17:56, 4 February 2026 (UTC)Reply

Reply 20-MAY-2026

[edit]

  Unable to implement  

  • Your edit request could not be implemented because the provided references are not formatted correctly.[a] The citation style predominantly used by the EyePoint Pharmaceuticals article is Citation Style 1 (CS1). The citation style used in the edit request consists of bare URL's linked with titles.[b] Any requested edit of yours which may be implemented will need to resemble the current style already in use in the article – in this case, CS1. (See WP:CITEVAR.) In the extended section below titled Citation style, I have illustrated two examples: one showing how the edit request was submitted, and another showing how requests should be submitted in the future:

Kindly resubmit the edit request below at your earliest convenience, taking care to ensure that it makes use of CS1. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards,  Spintendo  00:02, 21 May 2026 (UTC)Reply

Notes

  1. ↑ The fault for this formatting error may have originated with the automated prompts used by the edit request template, which asks for a COI editor to "supply the URL of any references used". While the resulting omission of information would not be the fault of the requesting COI editor, it nevertheless remains their responsibility to supply the references formatted in the style used by the article.
  2. ↑ The use of bare URLs as references is a style which is acceptable for use in Wikipedia. However, general practice dictates that the style already in use for an article be the one that is subsequently used for all future additions unless changed by editorial consensus.[1]

References

  1. ↑ "WP:CITEVAR - Wikipedia:Citing sources". Wikipedia. 20 October 2018. Retrieved 22 October 2018. Guideline: It is normal practice to defer to the style used by the first major contributor or adopted by the consensus of editors already working on the page, unless a change in consensus has been achieved. If the article you are editing is already using a particular citation style, you should follow it.